Acquired resistance to doxorubicin significantly reduces its therapeutic efficacy, limiting its clinical use in breast cancer treatment. Pan-AKR1C inhibitors have demonstrated potential in restoring ...

NS-229, an investigational selective Janus kinase 1 (JAK1) inhibitor developed by NS Pharma, has received Orphan Drug Designation from the US Food & Drug Administration (FDA) for the treatment of ...

Although antiviral drugs such as neuraminidase inhibitors are efficacious for postexposure prophylaxis, their greatest use has been in the treatment of existing illness to reduce symptoms and ...

The Food and Drug Administration (FDA ... NS-229 is an investigational selective Janus kinase 1 (JAK1) inhibitor designed to prevent tissue damage caused by EGPA by suppressing immune cell ...

200 mg every 7 days Age ≥ 12 yr: 100 mg twice daily for 5 days d Children Age ≥ 1 yr: twice daily for 5 days e a A new warning concerning adverse effects of oseltamivir is found at www.fda.gov ...

accepted a New Drug Application (NDA) for its new generation pan-TRK inhibitor zurletrectinib (ICP-723) for the treatment of adult and adolescent patients (12 to 18 years old) with advanced solid ...

The hybrid proteins retained the structure of the neuraminidase scaffold and the antigenicity ... four Beta strands and the Loops 12 and 34 we refer to as the “scaffold”. Oseltamivir is shown in red ...